Peritoneal Cancer Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

ASO Author Reflections: Achieving Long-Term Survival in Patients with Peritoneal Carcinomatosis of Colorectal Origin
Ann Surg Oncol. 2023 Dec 8. doi: 10.1245/s10434-023-14707-6. Online ahead of print.NO ABSTRACTPMID:38063982 | DOI:10.1245/s10434-023-14707-6 (Source: Ann Oncol)
Source: Ann Oncol - December 8, 2023 Category: Cancer & Oncology Authors: Elad Sarfaty Noah A Cohen Source Type: research

Cancers, Vol. 15, Pages 5710: Prognostic Factors Influencing Survival in Ovarian Cancer Patients: A 10-Year Retrospective Study
Conclusions: This study confirms that the FIGO stage, performance status, and surgery type were considered as prognostic factors for OS in ovarian cancer. (Source: Cancers)
Source: Cancers - December 5, 2023 Category: Cancer & Oncology Authors: Maria Andreou Maria Kyprianidou Christos Cortas Irene Polycarpou Demetris Papamichael Panteleimon Kountourakis Konstantinos Giannakou Tags: Article Source Type: research

Combined Intraperitoneal Paclitaxel and Systemic Chemotherapy for Patients with Massive Malignant Ascites Secondary to Pancreatic Cancer: A Report of Two Patients
Intern Med. 2023 Dec 4. doi: 10.2169/internalmedicine.2191-23. Online ahead of print.ABSTRACTThe prognosis of patients with peritoneal metastases from pancreatic cancer is poor, largely due to massive ascites, which precludes systemic treatment. Two patients with a poor performance status and malignant ascites were treated with cell-free and concentrated ascites reinfusion therapy followed by combined chemotherapy with intraperitoneal paclitaxel, intravenous gemcitabine, and nab-paclitaxel. These patients achieved a survival of 19 and 36 weeks with a relatively good quality of life. Combined intraperitoneal paclitaxel and ...
Source: Internal Medicine - December 3, 2023 Category: Internal Medicine Authors: Yoshiyuki Meguro Hironori Yamaguchi Hideki Sasanuma Kentaro Shimodaira Yuichi Aoki Takashi Chinen Kazue Morishima Hideyo Miyato Atsushi Miki Kazuhiro Endo Alan Kawarai Lefor Joji Kitayama Naohiro Sata Source Type: research

Cancers, Vol. 15, Pages 5694: Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success
hyden Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer. The disease is often diagnosed after wide-spread dissemination, and the standard treatment combines aggressive surgery with platinum-based chemotherapy; however, most patients experience relapse in the form of peritoneal carcinomatosis, resulting in a 5-year mortality below 45%. There is clearly a need for the development of novel treatments and cancer immunotherapies offering a different approach. Immunotherapies have demonstrated their efficacy in many types of cancers; however, only &lt;15% of EOC patients show any evidence of respo...
Source: Cancers - December 2, 2023 Category: Cancer & Oncology Authors: Galaxia M. Rodriguez Edward Yakubovich Barbara C. Vanderhyden Tags: Review Source Type: research

Retraction Note to: Mesothelial cells differentiate into fibroblast-like cells under the scirrhous gastric cancer microenvironment and promote peritoneal carcinomatosis in vitro and in vivo
Mol Cell Biochem. 2023 Dec 1. doi: 10.1007/s11010-023-04911-z. Online ahead of print.NO ABSTRACTPMID:38038799 | DOI:10.1007/s11010-023-04911-z (Source: Molecular and Cellular Biochemistry)
Source: Molecular and Cellular Biochemistry - December 1, 2023 Category: Biochemistry Authors: Zhi-Dong Lv Hai-Bo Wang Qian Dong Bin Kong Jian-Guo Li Zhao-Chuan Yang Hui-Li Qu Wei-Hong Cao Hui-Mian Xu Source Type: research

Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy
Conclusion: Targeted radionuclide therapy can be combined with Gd-NPs to increase the therapeutic effect and reduce the injected activities. As Gd-NPs are already used in the clinic, this combination could be a new therapeutic approach for patients with ovarian peritoneal carcinomatosis. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Garcia-Prada, C. D., Carmes, L., Atis, S., Parach, A., Bertolet, A., Jarlier, M., Poty, S., Garcia, D. S., Shin, W.-G., Du Manoir, S., Schuemann, J., Tillement, O., Lux, F., Constanzo, J., Pouget, J.-P. Tags: FEATURED ARTICLE OF THE MONTH Source Type: research

Cancers, Vol. 15, Pages 5661: Chimeric Antigen Receptor-T Cell and Oncolytic Viral Therapies for Gastric Cancer and Peritoneal Carcinomatosis of Gastric Origin: Path to Improving Combination Strategies
In this study, we provide an up-to-date review of the pre-clinical and clinical efficacy of CAR T cell therapy for key primary antigen targets and provide a translational overview of the types, modifications, and mechanisms for OVs used against GC and GCPC. Finally, we present a novel, summary-based discussion on the potential synergistic interplay between OVs and CAR T cells to treat GCPC. (Source: Cancers)
Source: Cancers - November 30, 2023 Category: Cancer & Oncology Authors: Courtney Chen Audrey Jung Annie Yang Isabel Monroy Zhifang Zhang Shyambabu Chaurasiya Supriya Deshpande Saul Priceman Yuman Fong Anthony K. Park Yanghee Woo Tags: Review Source Type: research

FDG-PET/MRI for the preoperative diagnosis and staging of peritoneal carcinomatosis: a prospective multireader pilot study
ConclusionFDG-PET/MRI achieved an excellent diagnostic accuracy per-patient and weaker performance per-region for detection of PC. The added value of PET/MRI compared to MRI and FDG-PET remains to be determined. (Source: Abdominal Imaging)
Source: Abdominal Imaging - November 29, 2023 Category: Radiology Source Type: research